Ayub leads the Cue team of scientists, chemists, statisticians, engineers, and individuals experienced in FDA clearance of diagnostic products and more who are committed to creating a new standard of care in diagnostics, with the ability to bridge the physical to virtual care continuum and benefit everyone by keeping people healthy and productive.
Under Ayub’s leadership, the company developed the Cue Health Monitoring System that enables fast, frequent, lab-quality diagnostics by anyone, anywhere. Cue’s first commercially available product, the Cue COVID-19 Test Kit, provides highly accurate, lab-quality results directly to connected mobile smart devices in about 20 minutes. The Cue COVID-19 Test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use, without physician supervision or a prescription.
The idea for Cue was conceived in 2010 when Ayub and co-founder & Chief Product Officer Clint Sever recognized the problems with how the current health structure collects, communicates, and uses health data. They saw the opportunity to create a new model for care and started Cue to create tools that empower healthcare providers and consumers by increasing their access to actionable health data.
Ayub received a Bachelor of Science degree in mathematics from the University of California, Los Angeles.
Clint leads product development and product design strategy at Cue, including the look and feel of Cue products, user interface, and packaging. Clint has overseen hardware engineering, supply chain development, and scaled manufacturing of Cue consumable cartridges, cartridge readers, and accessories. He is also responsible for the design and engineering of the facilities in which Cue products are made.
The idea for Cue was conceived in 2010 when Clint and co-founder & Cue CEO Ayub Khattak recognized the problems with how the current health structure collects, communicates, and uses health data. They saw the opportunity to create a new model for care and started Cue to create tools that empower healthcare providers and consumers by increasing their access to actionable health data.
Clint received a Bachelor of Science degree in retail and consumer science from the University of Arizona.
Chris has served as a member of the board of directors of the Network for Teaching Entrepreneurship since 2018. Chris holds a B.S. in business marketing from California State University and a M.B.A. from Pepperdine University School of Business.
As COO, David will oversee Cue Health’s worldwide supply chain, manufacturing operations, and expansion of its product line, positioning the Company for continued growth.
Prior to joining Cue Health, David served for a decade in multiple senior operational roles at Dexcom, a diabetes care technology company. He was most recently Dexcom’s senior vice president of global manufacturing operations. Before Dexcom, David held a number of management, consulting, and engineering positions at Alere (now Abbott), Amylin Pharmaceuticals (now AstraZeneca), and PRTM (now PWC).
David holds an MBA and a Masters in Engineering Management from Northwestern University as well as a Bachelor of Science in Chemical Engineering from Cornell.
At Cue, Allison is responsible for leading the strategic direction of its human resources function to support Cue’s overall goals. She has more than 20 years of experience in building and executing human resources, diversity & inclusion, and labor & employee relations functions within the healthcare space.
Allison most recently served as Vice President & Chief Diversity + Inclusion Officer for Danaher Corporation, where she developed and led initiatives that furthered Danaher’s commitment to D&I and delivered meaningful improvements across the company. Prior to that, she served as Vice President, Human Resources for Danaher’s Diagnostics and Life Sciences platforms.
Before her tenure at Danaher, Allison was Senior Vice President, Human Resources & Communications, at Beckman Coulter, Inc., where she was responsible for all aspects of human resources globally. Before joining Beckman Coulter, Blackwell held a number of leadership positions in HR and employee relations at the Target Corporation. She began her career as an attorney, serving as in-house employment counsel at HealthPartners and a litigation attorney at Oppenheimer, Wolff & Donnelly.
Allison received her B.A. in Economics from Carleton College and a J.D. from Boston College.
Nitin Duggal is Chief Marketing Officer of Cue Health, a healthcare technology company. At Cue, Nitin is responsible for leading all marketing initiatives at Cue, including partners, direct to consumer, customers, employers, and providers.
Nitin joined Cue from Abbott Diabetes Care where he spent 10 years in a number of leadership positions. He started his journey at Abbott as marketing lead for the launch of FreeStyle Libre in European markets. Subsequently, he launched different Libre products in the U.S. market as Senior Marketing Director. Nitin also established a digital health group in the U.S. to redefine the consumer journey and to explore alternate reimbursement models. Recently, Nitin worked as Senior Commercial Director in Abbott’s Biowearable group to promote and commercialize sensing technology among the non-diabetic population.
Prior to Abbott, Nitin was a consultant at McKinsey & Co and focused on the healthcare industry. During his stay at McKinsey, he led different engagements with payors and medical device companies.
Nitin received his MBA degree from Tuck School of Business at Dartmouth and holds an undergraduate degree in Electronics and Electrical Communication.
At Cue, Andy spearheaded the development of Cue’s mobile application software and system integration. Andy also helped lead the development and commercialization of Cue’s COVID-19 Test, which received an EUA from the FDA in June 2020 and the first-ever authorization of a molecular diagnostic test for non-prescription home use in March 2021.
In addition, Andy serves as program lead for Cue’s $481 million agreement with the U.S. Department of Defense to scale up Cue’s manufacturing and distribute 6 million COVID-19 tests, among other things. He also leads Cue’s $30 million contract with the HHS’s Biomedical Advanced Research and Development Authority (BARDA) to accelerate development of the Cue Health Monitoring system, including influenza and COVID tests.
Andy has served in a variety of leadership roles in R&D, operations, business development, and program management during his career. Prior to Cue, he was with Abbott (formerly Alere Inc.), where he led a global team focused on product development for the Toxicology Business Unit. Prior to Abbott, Andy was Director of Program Management and Corporate Business Development at Focus Diagnostics (formally a division of Quest Diagnostics).
Andy holds Bachelor and Master of Science degrees in biology from California State University, Long Beach.
Aasim Javed is Chief Financial Officer of Cue Health, a healthcare technology company. At Cue, Aasim is responsible for all the company’s internal and external facing financial functions, including financial planning and analysis, treasury, investor relations, accounting, tax, and audit.
Aasim joined the company in April 2021 as Corporate Treasurer and Head of Corporate Finance. Aasim led financial planning through the IPO, built the finance team, and closed a revolving credit facility for the company to increase overall liquidity. Aasim was appointed CFO in March 2023. Aasim has over seventeen years of experience in finance and accounting, having worked in a variety of finance roles at Becton Dickinson, HJ Heinz, and General Motors.
Aasim holds an MBA from Harvard Business School and received an undergraduate degree in Finance and Accounting from McGill University. In addition, Aasim is a Chartered Financial Analyst or CFA.
Deb provides leadership and direction for regulatory and clinical affairs at the company. She develops regulatory strategies, manages regulatory submissions, leads interactions with regulators, and directs and manages the clinical team in the design and execution of compliant, on-budget, and timely clinical studies.
Deb has over 40 years of experience in executive management and her expertise includes clinical and regulatory strategies for in-vitro diagnostics, clinical operations, protocol development, clinical trial management, data analysis, and U.S. and international regulatory submissions. Prior to Cue, she served as Senior Director, Clinical for Myraqa, a wholly-owned subsidiary of Illumina Inc.; Director, Regulatory Affairs Strategic Initiatives at GE Healthcare; and Senior Director, Clinical and Regulatory Affairs at Focus Diagnostics. Deb began her career at Ischemia Technologies and served in various clinical and regulatory affairs roles at Siemens Healthcare.
Over the course of her career, Deb has supported FDA Emergency Use Authorizations and numerous 510K clearances and PMA approvals for central lab and POC/CLIA Waived assays, including respiratory virus panels influenza A/H1N1/B and RSV cardiac risk markers; hsCRP; serology IgM/IgG; tumor markers (PSA, CEA, CA-125, CA15-3, CA19-9. AFP); Hepatitis B; intact PTH; vancomycin and instrumentation, including CLIA moderately complex integrated cyclers; and other random access automated analyzers.
Deb earned Master of Science degrees in biostatistics from New York Medical College and computer science from New York University. She also holds a Bachelor of Arts degree in biology from State University of New York at Albany.
At Cue, Erica oversees all legal, privacy, and compliance matters, including commercial contracting, employment, governance, intellectual property, and litigation.
Erica previously served as General Counsel, Corporate Secretary, and Privacy Officer for digital health company Livongo Health where she led the company’s legal, privacy, compliance, and regulatory affairs/quality management efforts, and advised the Board and executive management. Erica was responsible for the legal aspects of Livongo’s Series E private financing round, three acquisitions, its initial public offering, two secondary offerings, and a convertible debt offering until Livongo’s $18.5B acquisition by virtual healthcare provider Teladoc Health in October 2020.
Prior to Livongo, Erica spent seven years at Allscripts Healthcare, a leader in health information technology solutions, where she served as Corporate Counsel.
Erica received her Bachelor of Arts degree in political science from Loyola University Chicago and Juris Doctor from DePaul University College of Law.
David Tsay, M.D., Ph.D., is Chief Medical Officer of Cue Health, a healthcare technology company whose mission is to enable personalized, proactive, and informed healthcare that empowers people to live their healthiest lives.
Dr. Tsay oversees the Regulatory, Clinical, and Medical Affairs teams that support development of Cue diagnostic products and services. Dr. Tsay also leads clinical thought leadership and engagement for the company across a wide range of healthcare stakeholders to facilitate communication, collaboration, and ecosystem alignment in support of Cue’s healthcare initiatives.
Dr. Tsay has more than 20 years of experience in clinical medicine, research, and health technology. He most recently served at Apple, where he led an Apple Health clinical team in developing new Health products, including FDA-cleared products in cardiovascular health. Prior to Apple, Dr. Tsay served as Associate Chief Transformation Officer at New York-Presbyterian (NYP), one of the nation's most comprehensive academic healthcare delivery systems. He led digital transformation initiatives for NYP, including overseeing enterprise teams for data science, business intelligence, artificial intelligence, automation, and digital web/mobile technologies. He was previously a founding team member for NYP OnDemand, a comprehensive suite of digital health services.
Dr. Tsay was also an Assistant Clinical Professor of Medicine at Columbia University Medical Center. He received his BA in Computer Science and Physics at Columbia University College, and subsequently his M.D. and Ph.D. degrees from Columbia University College of Physicians and Surgeons. He is board certified in Internal Medicine and Cardiology and holds active medical licenses in both California and New York.